Evidence map›Paper›PMID 34977459›Full record

ArticleInternational journal of reproductive biomedicine2021

Comparing a biosimilar follitropin alfa (Cinnal-fⓇ) with Gonal-fⓇ in women undergoing ovarian stimulation: An RCT.

Batool Hossein Rashidi, Khashayar Sayyari, Ramin Heshmat, Saeid Amanpour, Ensieh Shahrokh Tehraninejad, Masoumeh Masoumi, Farhang Rezaei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of reproductive biomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Batool Hossein RashidiVali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-4897-0087
Khashayar SayyariFaculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ramin HeshmatChronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Saeid AmanpourVali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Ensieh Shahrokh TehraninejadVali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Masoumeh MasoumiVali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
Farhang RezaeiMedical Department, Orchid Pharmed Company, Tehran, Iran.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvances in recombinant DNA technology led to the development of recombinant follitropin alfa. Recombinant human follicle-stimulating hormone products are used to stimulate follicular maturation.

objectiveTo compare the efficacy and safety of a biosimilar-candidate recombinant human follicle-stimulating hormone (Cinnal-fⓇ; CinnaGen, Iran) with the reference product (Gonal-fⓇ; Merck Serono, Germany) in women undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI). MATERIALS AND

methodsIn this randomized controlled trial, a total sample size of 200 women (age

resultsA total of 208 women were enrolled, of whom, 200 completed the study period. Ovarian stimulation with Cinnal-fⓇ resulted in a comparable percentage of MII oocytes as with Gonal-fⓇ (78.64% vs 80.02%, respectively; p = 0.81). No statistically significant difference was seen in the secondary outcomes between the groups.

conclusionCinnal-fⓇ proved non-inferior to Gonal-fⓇ, based on the percentage of MII oocytes in women aged

Indexed as

BiosimilarEfficacyFollitropin alfaIntracytoplasmic sperm injection.Safety

Identifiers

PMID34977459
PMCPMC8717078
OpenAlexW4200614992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.